Manning & Napier Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Manning & Napier Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-154,597	Closed	-$63.5M	–	354
2019 Q1	$63.5M	Sell	154,597 -52,274	-25%	-$21.5M	0.69%	39
2018 Q4	$77.3M	Sell	206,871 -61,227	-23%	-$22.4M	0.94%	35
2018 Q3	$108M	Sell	268,098 -248,240	-48%	-$94.5M	1.06%	33
2018 Q2	$178M	Buy	516,338 +23,315	+5%	+$7.29M	1.76%	16
2018 Q1	$170M	Buy	493,023 +38,688	+9%	+$13.5M	1.67%	17
2017 Q4	$171M	Buy	+454,335	New	+$184M	1.54%	17

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Manning & Napier Group's REGN Position: Q2 2019 in Review

Manning & Napier Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 154,597 shares — an estimated $63.5M sold.

Manning & Napier Group first reported a position in REGN in Q4 2017 and held it in 6 quarters. The position peaked at $178M in Q2 2018. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

Manning & Napier Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Manning & Napier Group sold 154,597 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $63.5M.
Manning & Napier Group first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Manning & Napier Group's Regeneron Pharmaceuticals position peaked at $178M in Q2 2018.
658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Manning & Napier Group's 13F filing for Q2 2019, filed 24 Jul 2019.